Chen Jianwei, Zhang Hongfang, Wang Siqi, Du Yujie, Wei Bin, Wu Qiang, Wang Hong
College of Pharmaceutical Science and Collaborative Innovation Center of Yangtze River Delta Region Green Pharmaceuticals, Zhejiang University of Technology, Hangzhou, China.
State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Taipa, Macau SAR, China.
Front Microbiol. 2022 Feb 23;13:835058. doi: 10.3389/fmicb.2022.835058. eCollection 2022.
Both Gram-positive and Gram-negative bacteria can secrete extracellular vesicles (EVs), which contain numerous active substances. EVs mediate bacterial interactions with their hosts or other microbes. Bacterial EVs play a double-edged role in infections through various mechanisms, including the delivery of virulence factors, modulating immune responses, mediating antibiotic resistance, and inhibiting competitive microbes. The spread of antibiotic resistance continues to represent a difficult clinical challenge. Therefore, the investigation of novel therapeutics is a valuable research endeavor for targeting antibiotic-resistant bacterial infections. As a pathogenic substance of bacteria, bacterial EVs have gained increased attention. Thus, EV inhibitors are expected to function as novel antimicrobial agents. The inhibition of EV production, EV activity, and EV-stimulated inflammation are considered potential pathways. This review primarily introduces compounds that effectively inhibit bacterial EVs and evaluates the prospects of their application.
革兰氏阳性菌和革兰氏阴性菌均可分泌细胞外囊泡(EVs),这些囊泡含有多种活性物质。EVs介导细菌与宿主或其他微生物的相互作用。细菌EVs通过多种机制在感染中发挥双刃剑作用,包括传递毒力因子、调节免疫反应、介导抗生素耐药性以及抑制竞争性微生物。抗生素耐药性的传播仍然是一个严峻的临床挑战。因此,研究新型疗法以对抗耐药菌感染是一项有价值的研究工作。作为细菌的一种致病物质,细菌EVs已受到越来越多的关注。因此,EV抑制剂有望作为新型抗菌剂发挥作用。抑制EV产生、EV活性以及EV刺激的炎症被认为是潜在的途径。本综述主要介绍有效抑制细菌EVs的化合物,并评估其应用前景。